Evidence map›Paper›PMID 42444859›Full record

ArticleJournal of thoracic disease2026

Liming Chen, Shuping Cheng, Pengcheng Liu, Juan Jiang, Houhui Jiang, Rui Wu, Shujiao Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liming ChenDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Shuping ChengDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Pengcheng LiuDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Juan JiangDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Houhui JiangDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Rui WuDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
Shujiao YuDepartment of Rheumatology, The First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: As a progressive and fatal interstitial lung disease, the treatment options for idiopathic pulmonary fibrosis (IPF) are currently limited. Methods: A rat IPF model was built via intratracheal instillation of bleomycin (5 mg/kg), and rats were divided into sham, IPF, IPF + TWGT (6 mg/kg), IPF + prednisolone acetate (PA) (3 mg/kg), and IPF + TWGT + PA groups. Lung tissues were collected at 7, 14, and 28 days post-modeling for histopathological evaluation, transcriptome sequencing, and immunofluorescence staining. Serum levels of cytokines were measured by enzyme-linked immunosorbent assay (ELISA), and Th17 cell proportions were analyzed by flow cytometry. Results: Histopathological results showed that TWGT significantly alleviated alveolar structural damage, inflammatory cell infiltration, and collagen deposition at 7, 14, and 28 days post-modeling. Transcriptome analysis identified 364 and 2,271 differentially expressed genes (DEGs) in IPF Conclusions: These data show an association between TWGT treatment and changes in the TGF-β/IL-17 axis and Th17 responses, suggesting that this pathway may be involved.

Indexed as

inflammatory cytokinesInterstitial pulmonary fibrosis (IPF)Th17 cellstransforming growth factor β (TGF-β)Tripterygium wilfordii glycoside tablets (TWGT)

Identifiers

PMID42444859
PMCPMC13358510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.